Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2009. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
No material changes to financial performance or operations are reported in this filing. The only reported activity is an increase in shareholdings for specific individuals following the re-investment of dividends paid on July 9, 2009.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly details the purchase of Ordinary shares at a price of £11.18 per share on July 15, 2009, by the following individuals:
- Mr A P Witty: 132 shares
- Dr M M Slaoui: 293 shares
- Mr M Dunoyer: 141 shares
- Dr D Pulman: 217 shares
- Ms C Thomas: 55 shares
Key Facts for Investor Verification
- Verify the dividend re-investment plan details for the July 9, 2009 payment.
- Confirm the share price of £11.18 per share on July 15, 2009.
- Check subsequent filings for comprehensive financial results, as this 6-K does not contain financial statements.